Characterization of New Hematological Markers of Inflammation in Patients with Acute Heart Failure
Keywords:
cardiovascular diseases, heart failure, inflammationAbstract
Introduction: Heart failure is a frequent cause of hospitalization and increased mortality; However, in terms of prediction, new hematological markers of inflammation have been little explored in our population.
Objective: To characterize the relationship between complications that occurred during hospitalization for acute heart failure and hematological markers of inflammation obtained upon admission.
Methods: A cross-sectional descriptive study was carried out on 100 patients with acute heart failure, admitted to the Cardiology ward of the Saturnino Lora Provincial Clinical-Surgical Teaching Hospital of Santiago de Cuba, from January 2020 to the same month of 2022. They were analyzed. hematological variables and clinical course.
Results: The majority of patients had a clinical course without complications (63.0%) and with neutrophil/lymphocyte ratio values less than 2.9 (93.4%) of the cases. 77.2% of the patients were discharged alive; while in the deceased and complicated patients the values of the neutrophil/lymphocyte and platelet/lymphocyte ratio were higher, it is highlighted that 100% of the deceased had an RPL ≥ 116.
Conclusions: It is demonstrated that the values of hematological markers of inflammation and stress oxidative stress are associated with major complications and mortality in patients hospitalized for acute heart failure, which is why they could be useful for prognostic stratification and establishing more effective therapeutic guidelines in patients with said diagnosis.
Downloads
References
1. Organización Mundial de la Salud. Cardiovascular diseases. Ginebra: OMS; 2023 [acceso 05/03/2023]. Disponible en: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
2. De Abreu M, Vensentini N, Mariani J, Gagliardi J, Doval H, Tajer C. Síndromes coronarios agudos en instituciones públicas y no públicas de Argentina. Medicina (B. Aires). 2019 [acceso 12/07/2021];79(6):461-7. Disponible en: https://search.bvsalud.org/gim/resource/es/biblio-1056754
3. Gaviria S, Ramírez A, Alzate M, Contreras H, Jaramillo N, Muñoz MC. Epidemiología del síndrome coronario agudo. Med UPB. 2020;39(1):49-56. DOI https://doi.org/10.1856/medupb.v39n1.a08
4. Ruparelia N, Choudry R. Inflammation and atherosclerosis; What is on The Horizons? Heart. 2020;106(1):80-5 DOI: https://doi.org/10.1136/heartjnl-2018-314230
5. Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost. 2019;4(1):23-35. DOI: https://doi.org/10.1002/rth2.12266
6. Fong Ocejo M, Téllez Gamayo G, Martínez Sole EA, Tamayo Blanco D. Caracterización de los pacientes con edema agudo del pulmón en el servicio de urgencias. MEDISAN. 2024 [acceso 23/11/2024];28(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci-arttext&pid=S1029-30192024000200010&Ing=es
7. Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18(12):733-44. DOI: https://doi.org/10.1038/s41577-018-0065-8
8. Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(11):1324-40. DOI: https://doi.org/10.1016/j.jacc.2020.01.014
9. Ridker P, Libby P, MacFadyen JD, Thuren T, Ballantyne T Ch, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European Heart Journal. 2018;39(38):3499-507. DOI: https://doi.org/10.1093/eurheartj/ehy310
10. Konradi J, Mollenhauer M, Baldus S, Klinke A. Redox-sensitive mechanisms underlying vascular dysfunction in heart failure. Free radical Research. 2015;49(6):721-42. DOI: https://doi.org/10.3109/10715762.2015.102720
11. Meier S, Henkens M, Heymans S, Robinson EL. Unlocking the value of white blood cells for heart failure diagnosis. J Cardiovascular Transl Res. 2021;14(1):53-62. DOI: https://doi.org/10.1007/s12265-020-10007-6
12. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The Role of Hematological Indices in Patients with Acute Coronary Syndrome. Disease Markers. 2017;(9):1-9. DOI: https://doi.org/10.1155/2017/3041565
13. Morici N, Cantoni S, Soriano F, Viola G, De Stefano V, Veas N, et al. Relevance of complete blood count parameters in the assessment of acute coronary syndromes: a combined hematological and cardiological perspective. G Ital Cardiol. 2019;20(12):694-705. DOI: https://doi.org/10.1714/3271.32379
14. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. Guía sobre la revascularización coronaria de ACC/AHA/SCAI de 2021. J Am Coll Cardiol. 2022;79(2):e21-e129. DOI: https://doi.org/10.1016/j.jacc.2021.09.006
15. Zeppenfeld K, Tfelt-Hansen J, Riva M, Winkel GB, Behr RE, Blom NA, et al. 2022 ACC/AHA/HRS Guideline for Management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. DOI: https://doi.org/10.1093/eurheartj/ehac262
16. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay. J Am Coll Cardiol. 2019;74(7):51-156. DOI: https://doi.org/10.1016/j.jacc.2018.10.044
17. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash MI, et al. Guía ESC 2021 sobre estimulación cardíaca y terapia de resincronización. Rev Esp Cardiol. 2022;75(5):1-86. DOI: https://doi.org/10.1016/j.recesp.2021.10.025
18. Alonso Mendoza LA. Manejo diagnóstico y principales hallazgos en pacientes con insuficiencia cardíaca, ingresados al Servicio de Medicina Interna, HEODRA, León, durante 2017-2018. [Tesis]. León: Universidad Nacional Autónoma de Nicaragua; 2020. Disponible en: http://riul.unanleon.edu.ni:8080/jspui/handle/123456789/4835
19. Delcea C, Buzea CA, Dan GA. The neutrophil to lymphocyte ratio in heart failure: a comprehensive review. Rom. J. Intern Med. 2019;57(4):296-314. DOI: https://doi.org/10.2478/rjim-2019-0018
20. Turcato G, Sanchis GF, Cervellin G, Zorzi E, Sivero V, Salvagno GL, et al. Evaluation of neutrophil-lymphocyte and platelet-lymphocyte ratios as predictors of 30-day mortality in patients hospitalized for an episode of acute decompensated heart failure. J Med Biochem. 2019;38(4):452-60. DOI: https://doi.org/10.2478/jomb-2018-0044
21. Angkananard T, Anothaisintawee T, McEvoy M, Attia J, Thakkinstian A. Neutrophil Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis. BioMed Research International. 2018;2018:1-11. DOI: https://doi.org/10.1155/2018/2703518
22. Xu N, Tang XF, Yao Y, Zhao X, Chen J, Gao Z, et al. Predictive value of neutrophil to lymphocyte ratio in long-term outcomes of left main and/or three-vessel disease in patients with acute myocardial infarction. Catheter Cardiovasc Interv. 2018;91(S1):551-7. DOI: https://doi.org/10.1002/ccd.27495
23. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The Role of Hematological Indices in Patients with Acute Coronary Syndrome. Disease Markers. 2017;(9):1-9. DOI: https://doi.org/10.1155/2017/3041565
24. Vakili H, Shirazi M, Charkhkar M, Khaheshi I, Memaryan M, Naderian M. Correlation of platelet to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction. Eur J Clin Invest. 2017;47(4):322-7. DOI: https://doi.org/10.1111/eci.12736
25. Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F. Heart Failure and Liver Disease: Cardiohepatic interactions. JACC Heart Fail. 2019;7(2):87-97. DOI: https://doi.org/10.1016/j.chf.2018.10.007
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Lucia Nivia Turro Mesa, Germán Del Río Caballero, Rita María Mesa Valiente, German Ricardo del Río Mesa, Eloy Turro Caró
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Attribution-NonCommercial 4.0 Internacional (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. o admite fines comerciales. Permite copiar, distribuir e incluir el artículo en un trabajo colectivo (por ejemplo, una antología), siempre y cuando no exista una finalidad comercial, no se altere ni modifique el artículo y se cite apropiadamente el trabajo original. El Comité Editorial se reserva el derecho de introducir modificaciones de estilo y/o acotar los textos que lo precisen, comprometiéndose a respectar el contenido original.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
